cell cultures (4) and decreased the relapse rate in MS patients (14) . However, the role of theophylline in the treatment of MS exacerbation was not investigated in previous studies.
In this study, our aim was to evaluate whether addition of theophylline to pulse intravenous methylprednisolone treatment in relapses of MS was associated with improvement in clinical scores and decrease in TNF-alpha levels. We have also evaluated whether there was a relationship between severity of MS relapses and pulmonary function test (PFT).
Material and Methods

Patients
In this double blind placebo controlled trial of add-on therapy, 24 patients, 14 female and 10 male, with relapsing-remitting MS having at least one relapse in the past year were recruited. Demographic data of the study population was presented in Table 1 . All subjects were diagnosed as having relapsing remitting definite MS according to Mc Donald's criteria (19) . Patients were eligible for the study if they had a diagnosis of definite MS and had suffered a relapse, defined as the occurrence, recurrence, or worsening of symptoms of neurological dysfunction lasting more than 24 hours. Fatigue alone and transient feverrelated worsening of symptoms were not considered to be a relapse, and symptoms that occurred within 1 month of each other were considered to be part of the same relapse (20) . No patient with MS had received any immunomodulatory or immunosuppressant treatment for at least 3 months prior to the study. Patients had not suffered from any concomitant disease before or during the study. Informed consent was obtained from all subjects. The mean age of the group was (32.6±9), the mean duration of illness was (5.4±4.2) years and the number of exacerbations was 5±2. Kurtzke's expanded disability status scale (EDSS) was evaluated by a neurologist at the baseline, 5th and 30th days of the treatment.
Study design
The study was incorporated as a randomized, doubleblind and placebo controlled design. The baseline EDSS score was determined, PFT was performed and blood was taken for analysis of TNF-alpha levels before the study. All patients received intravenous (IV) methylprednisolone (1000 mg/day) treatment. In group 1, IV theophylline (Aminocardol ® 400 mg ampule, Novartis, Basel, Switzerland) was added onto intravenous methylprednisolone treatment, while group 2 received IV placebo (physiological serum) for 5 days. PFT and EDSS score were repeated and blood was taken for TNF-alpha on the 5 th and 30 th days of the treatment. The serum concentration of theophylline was measured on day 5. EDSS rater neurologist was blinded to the treatment.
The study protocol was approved by the ethics committee and all patients gave written informed consent.
PFT measurement
Spirometry was performed using a Sensormedics Vmax 20C (Sensormedics, Yorba Linda, CA, USA). Forced expiratory volume in one second (FEV 1 ), forced vital capacity (FVC), FEV 1 /FVC ratio, and vital capacity (VC) were measured. Carbon monoxide diffusing capacity (DLCO) was also determined using the single-breath CO method.
TNF-alpha measurement
Blood was collected in vacutainer tubes and incubated at room temperature for 60-120 minutes. They were then centrifuged at 1300g for 10 minutes. The serum was aspirated and stored at -20°C for later analysis. The TNF-alpha levels were assessed by enzyme-linked immunosorbant assay (CytElisa, CYTimmune Sciences, MD, USA). The results were expressed as picogram per liter and adjusted for the dilution factor.
Statistical analysis
All statistical analyses were performed on SPSS for Windows version 13.0 (SPSS, Chicago, IL, USA). Data were expressed as mean±SD. Between-group-change outcome variables were determined by the non-parametric Mann-Whitney U test. Within-group-change outcome variables were compared with the Wilcoxon paired test. Symptom scores were determined by chisquared analysis. p<0.05 was considered significant.
Results
A total of 24 patients were included in the study. Mean age was 32.6±9 years, duration of disease was 5.4±4.2 years, number of exacerbations was 5±2. There was no between group differences with respect to demographic data, baseline EDSS score and pulmonary function test parameters. Baseline serum TNF-alpha levels were higher in the theophylline group compared to placebo, however it was not statistically significant (Table 1) .
EDSS score was significantly reduced in the theophylline group while the decrease was not statistically significant in the placebo group (Figure 1 ). Serum TNF-alpha level did not change significantly in either of the groups. However, there was a non-significant reduction on 5 th day of the theophylline treatment and the TNF-alpha levels increased significantly on day 30 after theophylline was stopped (Figure 2 ). The EDSS score and levels of TNF-alpha on baseline, day 5 and day 30 in both groups were given in Table 2 .
In the pulmonary function test analysis, restrictive disorder was noticed in 8 patients and DLCO was found to be reduced in 3 patients. There was no significant correlation between the pulmonary function test with EDSS score and TNF-alpha levels. There was a significant correlation between the number of exacerbations and EDSS score (p=0.000, r=1).
Discussion
Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system. MS is characterised by the presence of demyelinated, sclerotic plaques in the central nervous system (CNS). In localised areas of inflammation, oligodendrocytes undergo necrosis and/or apoptosis, which lead to the loss of oligodendrocytes and the development of demyelination. Although the pathogenesis of MS is still unclear, recent studies suggest that proinflammatory cytokines, such as TNF-alpha, play critical roles in the development of the disease as effector molecules (1-3) .
TNF-alpha is thought to be one of the mediators responsible for the damage of oligodendrocytes in MS. TNF-alpha is produced by both macrophages and microglia in MS lesions and precedes the production of IL-12. IL-12 promotes the acquisition of a Th1 cytokine profile by CD4/ T cells, which also secrete TNF-alpha (4-5). Specific to autoreactivity, activated myelin basic protein (MBP) -reactive T cells secrete IFN-g, TNF-alpha and IL-2.23. Lymphotoxin (LT, TNF-beta) has also been localized in MS lesions. Therefore, the presence of TNFalpha in MS lesions has been noted and mechanisms for its appearance have been suggested. Also , levels of TNF-alpha correlate with clinical disease progression (4) (5) (6) . In this study serum TNF-alpha level was not changed in the placebo group, there was a non-significant decrease on day 5 and increase on day 30 in the theophylline group.
Methylprednisolone (MP) plays an important role in the current treatment of multiple sclerosis (MS), particularly in the acute phase of relapse. It acts in various ways to decrease the inflammatory cycle including: dampening the inflammatory cytokine cascade, inhibiting the activation of T cells, decreasing the extravasations of immune cells into the central nervous system, facilitating the apoptosis of activated immune cells, and indirectly decreasing the cytotoxic effects of nitric oxide and TNF-alpha. MP (21, 22, 23) . In this study serum TNF-alpha level was not changed in the placebo group, there was a nonsignificant decrease on day 5 and increase on day 30 in the theophylline group. There was no correlation between the clinical parameters, PFT and TNF-alpha level.
Phosphodiesterases (PDEs) are involved in the regulation of intracellular levels of the second messengers cyclic adenosinemonophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) (15) . In the cells of the immune system, increased intracellular levels of cAMP activate protein kinase A (PKA), which is a potent inhibitor of the immune system (12) (13) (14) (15) (16) . Intracellular cAMP levels are regulated by G-proteincoupled receptors, adenylyl cyclases (ACs) and PDEs (17) . In immune cells, cAMP is cleaved predominantly by phosphodiesterases 4 (PDE-4) and 3 (PDE-3) as T-cell activation and cytokine secretion (17) (18) (19) . Studies with the selective PDE4 inhibitor rolipram have demonstrated the efficacy of the compound in this disease model, suggesting that PDE4 inhibitors could ameliorate the clinical course of MS (10) . The effects of the PDE inhibitor pentoxifylline on cytokine production and other immune variables were tested in MS patients. In all studies, efficacy of pentoxifylline in the treatment for MS was not observed (23) (24) (25) . The within group analysis in this study showed that the EDSS score was decreased on day 5 and still low on day 30 in the theophylline group, there was no statistically significant difference in the EDSS score of the placebo group.
Respiratory complications are common in the terminal stages of multiple sclerosis and contribute to mortality in these patients. Respiratory muscle weakness may also occur early in the course of the disease (26) . In the pulmonary function test analysis; restrictive disorder was noticed in 8 patients Table 2 . Mean EDSS and TNF-alpha levels of the groups and DLCO was found to be reduced in 3 patients. There was no significant correlation between the pulmonary function test with EDSS score and TNF-alpha levels. Most studies (including ours) that have measured the levels of cytokines and chemokines before and after steroid therapy in MS patients in relapse have not used a not-treatment MS group. A comparison with cytokine levels of not-treated patients in relapse would be useful to determine how the levels evolve in this group of patients. Such a group is very difficult and maybe not be ethical, since most patients with a relapse should start treatment with steroids as soon as possible (19) (20) (21) . In this study, there was no correlation between severity of MS and PFT findings, within-group analysis EDSS score was found to be decreased on day 5 and still low on day 30 in the theophylline group, there was no statistically significant difference in the EDSS score of the placebo group. It is suggested that theophylline might be effective in MS exacerbation since it causes decreases in EDSS scores; studies with longer treatment duration are needed to clarify its possible anti-inflammatory effect. 
